In conclusion, the authors revealed that NAT10-mediated ac4C modification promotes the progression of RB by improving the HK1 mRNA stability to enhance glycolysis, which suggested that targeted regulation of ac4C modification may be an effective therapy approach for the treatment of RB. This evidence concerns the gene NAT10 and retinoblastoma.